Search Results - "Boe Sorensen"

Detection of EGFR mutations in plasma and biopsies from non-small cell lung cancer patients by allele-specific PCR assays by Weber, Britta, Meldgaard, Peter, Hager, Henrik, Wu, Lin, Wei, Wen, Tsai, Julie, Khalil, Azza, Nexo, Ebba, Sorensen, Boe S

“…Lung cancer patients with mutations in the epidermal growth factor receptor (EGFR) are primary candidates for EGFR-targeted therapy. Reliable analyses of such…”
Get full text

Monitoring of epidermal growth factor receptor tyrosine kinase inhibitor‐sensitizing and resistance mutations in the plasma DNA of patients with advanced non–small cell lung cancer during treatment with erlotinib by Sorensen, Boe S., Wu, Lin, Wei, Wen, Tsai, Julie, Weber, Britta, Nexo, Ebba, Meldgaard, Peter

“…BACKGROUND The feasibility of monitoring epidermal growth factor receptor (EGFR) mutations in plasma DNA from patients with advanced non–small cell lung cancer…”
Get full text

Increased Soluble PD-1 Predicts Response to Nivolumab plus Ipilimumab in Melanoma by Pedersen, Jesper, Sokac, Mateo, Sørensen, Boe, Luczak, Adam, Aggerholm-Pedersen, Ninna, Birkbak, Nicolai, Øllegaard, Trine, Jakobsen, Martin

“…Background: Checkpoint inhibitors have revolutionized the treatment of metastatic melanoma, yielding long-term survival in a considerable proportion of the…”
Get full text

Expression of the non-coding RNA nc886 facilitates the development of tyrosine kinase inhibitor resistance in EGFR-mutated non-small-cell lung cancer cells by Bui, Vivian N.V., Daugaard, Tina F., Sorensen, Boe S., Nielsen, Anders L.

“…Treatment of non-small-cell lung cancer (NSCLC) patients possessing EGFR-activating mutations with tyrosine kinase inhibitors (TKIs) can confer an initial…”
Get full text

Plasma Immune Proteins and Circulating Tumor DNA Predict the Clinical Outcome for Non-Small-Cell Lung Cancer Treated with an Immune Checkpoint Inhibitor by Stensgaard, Simone, Thomsen, Astrid, Helstrup, Sofie, Meldgaard, Peter, Sorensen, Boe S

“…Immunotherapy has altered the therapeutic landscape for patients with non-small-cell lung cancer (NSCLC). The immune checkpoint inhibitor pembrolizumab targets…”
Get full text

Exosomal proteins as potential diagnostic markers in advanced non-small cell lung carcinoma by Jakobsen, Kristine R., Paulsen, Birgitte S., Bæk, Rikke, Varming, Kim, Sorensen, Boe S., Jørgensen, Malene M.

“…Lung cancer is one of the leading causes of cancer-related death. At the time of diagnosis, more than half of the patients will have disseminated disease and,…”
Get full text

Correlation between early dynamics in circulating tumour DNA and outcome from FOLFIRI treatment in metastatic colorectal cancer by Lyskjær, Iben, Kronborg, Camilla Skovhus, Rasmussen, Mads Heilskov, Sørensen, Boe Sandahl, Demuth, Christina, Rosenkilde, Mona, Johansen, Amanda Frydendahl Boll, Knudsen, Michael, Vang, Søren, Krag, Søren Rasmus Palmelund, Spindler, Karen-Lise Garm, Andersen, Claus Lindbjerg

“…Chemotherapy resistance remains a challenge in the clinical management of metastatic colorectal cancer (mCRC). Here, early changes in cell-free circulating…”
Get full text

Comparison of culture media reveals that non-essential amino acids strongly affect the phenotype of human monocyte-derived macrophages by Antonsen, Kristian W, Friis, Henriette N, Sorensen, Boe S, Etzerodt, Anders, Moestrup, Søren K, Møller, Holger J

“…Macrophages are important innate immune cells with the ability to adapt their phenotype to environmental cues. Research on human macrophages often uses…”
Get full text

Blood tumor mutational burden and dynamic changes in circulating tumor DNA predict response to pembrolizumab treatment in advanced non-small cell lung cancer by Stensgaard, Simone, Thomsen, Astrid, Helstrup, Sofie, Meldgaard, Peter, Sorensen, Boe S.

Get full text

Increased PD-L1 expression in erlotinib-resistant NSCLC cells with MET gene amplification is reversed upon MET-TKI treatment by Demuth, Christina, Andersen, Morten Nørgaard, Jakobsen, Kristine Raaby, Madsen, Anne Tranberg, Sørensen, Boe Sandahl

“…Cancer cells can achieve immune evasion by expressing the programmed death receptor 1 ligand (PD-L1) on the cell surface. Blockade of the receptor (PD-1) can…”
Get full text

Erlotinib accumulation in brain metastases from non-small cell lung cancer: visualization by positron emission tomography in a patient harboring a mutation in the epidermal growth factor receptor by Weber, Britta, Winterdahl, Michael, Memon, Ashfaque, Sorensen, Boe S, Keiding, Susanne, Sorensen, Leif, Nexo, Ebba, Meldgaard, Peter

“…Drugs directed toward the epidermal growth factor receptor (EGFR), such as erlotinib (Tarceva®) and gefitinib (Iressa®), are used for the treatment of patients…”
Get more information

Co-occurring MET Amplification Predicts Inferior Clinical Response to First-Line Erlotinib in Advanced Stage EGFR-Mutated NSCLC Patients by Clement, Michelle S., Ebert, Eva Boysen Fynboe, Meldgaard, Peter, Sorensen, Boe S.

“…•Genetic alterations co-occur with epidermal growth factor receptor (EGFR) mutations in treatment naïve, EGFR-mutated, advanced stage non-small cell lung…”
Get full text

Proinflammatory polarization strongly reduces human macrophage in vitro phagocytosis of tumor cells in response to CD47 blockade by Antonsen, Kristian W., Jensen, Anne G., Carstensen, Mikkel, Nejsum, Lene N., Sorensen, Boe S., Etzerodt, Anders, Moestrup, Søren K., Møller, Holger J.

“…Antibody‐based CD47 blockade aims to activate macrophage phagocytosis of tumor cells. However, macrophages possess a high degree of phenotype heterogeneity…”
Get full text

TERT promoter mutated circulating tumor DNA as a biomarker for prognosis in hepatocellular carcinoma by Oversoe, Stine K., Clement, Michelle S., Pedersen, Michael H., Weber, Britta, Aagaard, Niels Kristian, Villadsen, Gerda E., Grønbæk, Henning, Hamilton-Dutoit, Stephen J., Sorensen, Boe S., Kelsen, Jens

“…Plasma circulating tumor DNA (ctDNA) with tumor-specific mutations is an attractive biomarker. The telomerase reverse transcriptase (TERT) C228T promoter…”
Get full text

Positron Emission Tomography (PET) Imaging with [11C]-Labeled Erlotinib: A Micro-PET Study on Mice with Lung Tumor Xenografts by MEMON, Ashfaque A, JAKOBSEN, Steen, DAGNAES-HANSEN, Frederik, SORENSEN, Boe S, KEIDING, Susanne, NEXO, Ebba

“…Erlotinib (Tarceva) targets the epidermal growth factor receptor (EGFR), which is commonly overexpressed in human cancers, including lung cancer. We show that…”
Get full text

Performance characteristics of a polymerase chain reaction-based assay for the detection of EGFR mutations in plasma cell-free DNA from patients with non-small cell lung cancer using cell-free DNA collection tubes by May, Theresa, Clement, Michelle S, Halait, Harkanwal, Kohlmann, Alexander, Kohlmann, Milena, Lai, Jason, Lee, Nitta, Li-Sucholeiki, Xiaocheng, Meldgaard, Peter, Joshi, Snehal, Scudder, Sidney, Shrestha, Neelima, Sorensen, Boe, Kiral, Marilyn, O'Donnell, Patrick

“…Survival rates in non-small cell lung cancer (NSCLC) are low. Detection of circulating tumor DNA in liquid biopsy (plasma) is increasingly used to identify…”
Get full text

Estrogen receptor α is the major driving factor for growth in tamoxifen-resistant breast cancer and supported by HER/ERK signaling by Thrane, Susan, Lykkesfeldt, Anne E., Larsen, Mathilde S., Sorensen, Boe S., Yde, Christina W.

“…Resistance to tamoxifen is a major clinical challenge in the treatment of breast cancer; however, it is still unclear which signaling pathways are the major…”
Get full text

Inflammatory Cytokines and ctDNA Are Biomarkers for Progression in Advanced-Stage Melanoma Patients Receiving Checkpoint Inhibitors by Pedersen, Jesper Geert, Madsen, Anne Tranberg, Gammelgaard, Kristine Raaby, Aggerholm-Pedersen, Ninna, Sørensen, Boe Sandahl, Øllegaard, Trine Heide, Jakobsen, Martin Roelsgaard

“…Checkpoint inhibitors have significantly improved treatment of metastatic melanoma. However, 40-60% of patients do not respond to therapy, emphasizing the need…”
Get full text

Co‐expression of HER3 and MUC1 is associated with a favourable prognosis in patients with bladder cancer by Nielsen, Trine O., Borre, Michael, Nexo, Ebba, Sorensen, Boe S.

“…Objectives To investigate the functional impact of the interaction of MUC1 with the epidermal growth factor receptors HER3 and HER4 in patients with bladder…”
Get full text

Examination of the Functional Relationship between PD-L1 DNA Methylation and mRNA Expression in Non-Small-Cell Lung Cancer by Larsen, Trine V, Dybdal, Nina, Daugaard, Tina F, Lade-Keller, Johanne, Lin, Lin, Sorensen, Boe S, Nielsen, Anders L

“…Immunotherapy targeting the interaction between programmed cell death protein 1 (PD-1) and programmed death-ligand 1 (PD-L1) is a treatment option for patients…”
Get full text